|1.||Minamoto, Toshinari: 8 articles (02/2015 - 01/2006)|
|2.||Kawakami, Kazuyuki: 6 articles (10/2013 - 01/2006)|
|3.||Nakada, Mitsutoshi: 5 articles (02/2015 - 02/2009)|
|4.||Lin, Chiou-Feng: 5 articles (11/2014 - 09/2009)|
|5.||Motoo, Yoshiharu: 5 articles (01/2013 - 01/2006)|
|6.||Thiemermann, Christoph: 5 articles (01/2012 - 01/2007)|
|7.||Werstuck, Geoff H: 4 articles (05/2015 - 01/2006)|
|8.||Chen, Chia-Ling: 4 articles (11/2014 - 09/2009)|
|9.||Shimasaki, Takeo: 4 articles (01/2013 - 12/2009)|
|10.||Huang, Wei-Ching: 4 articles (06/2012 - 09/2009)|
08/01/2009 - "Furthermore, we found a significant reduction in the levels of glycogen synthase kinase 3beta (GSK-3beta) protein in the tumors relative to OB. "
05/01/2015 - "Clinical significance of inactivated glycogen synthase kinase 3β in HPV-associated cervical cancer: Relationship with Wnt/β-catenin pathway activation."
03/01/2015 - "In the absence of Wnt signal (off-state), β-catenin prevents phosphorylation of glycogen synthase kinase (GSK)-3β leading to aberrant nuclear accumulation in human tumors. "
10/01/2014 - "Emerging evidence indicates that activation of Wnt/β-catenin signaling at the cell surface results in inhibition of glycogen synthase kinase 3β (GSK3β), leading to activation of mTORC1 signaling in cancer cells. "
01/01/2013 - "Glycogen synthase kinase 3β (GSK3β) regulates multiple cellular pathways and is implicated in various diseases including cancer. "
12/01/2008 - "We investigated the role of the Akt-glycogen synthase kinase (GSK)-3beta signalling pathway in mediating the protective effects of tissue kallikrein on myocardial injury by promoting angiogenesis and blood flow in rats after myocardial infarction (MI). "
05/01/2006 - "Inhibition of glycogen synthase kinase enhances isoflurane-induced protection against myocardial infarction during early reperfusion in vivo."
03/15/2015 - "Overexpression of protein phosphatase 2A in a murine model of chronic myocardial infarction leads to increased adverse remodeling but restores the regulation of β-catenin by glycogen synthase kinase 3β."
|3.||Adenomatous Polyposis Coli (Familial Adenomatous Polyposis)
06/01/2012 - "Binding of adenomatous polyposis coli (APC) to the microtubule plus ends in polarized cells is regulated by glycogen synthase kinase 3β (GSK-3β). "
10/28/2011 - "Expression of β-catenin is strictly regulated in normal cells via the glycogen synthase kinase 3β (GSK3β)- adenomatous polyposis coli-axin-mediated degradation pathway. "
05/01/2011 - "Activation of this signaling pathway causes disruption of the Axin/adenomatous polyposis coli/glycogen synthase kinase 3β complex, resulting in stabilization of β-catenin and its association with lymphoid enhancer factor/T-cell factor in the nucleus. "
01/28/1999 - "The adenomatous polyposis coli (APC) tumour-suppressor protein controls the Wnt signalling pathway by forming a complex with glycogen synthase kinase 3beta (GSK-3beta), axin/conductin and betacatenin. "
07/01/2011 - "Hypoxia significantly decreased β-catenin protein, but had no effect on glycogen synthase kinase (GSK)-3β or adenomatous polyposis coli (APC) levels. "
10/24/2008 - "Inhibition of glycogen synthase kinase (GSK)-3 reduces ischemia/reperfusion injury by mechanisms that involve the mitochondria. "
05/01/2006 - "Inhibition of glycogen synthase kinase (GSK)-beta protects against ischemia-reperfusion injury. "
02/01/2012 - "Therefore, in this study, we aimed to investigate whether delayed administration of parecoxib inhibited mitochondria-mediated neuronal apoptosis induced by ischemic reperfusion injury via phosphorylating Akt and its downstream target protein, glycogen synthase kinase 3β (GSK-3β). "
11/01/2015 - "Diverse transmitting pathways trigger a variety of signaling cascades, including the reperfusion injury salvage kinase and survivor activating factor enhancement pathways, all of which converge on glycogen synthase kinase 3β (GSK3β). "
11/01/2013 - "Role of glycogen synthase kinase 3β in protective effect of propofol against hepatic ischemia-reperfusion injury."
05/01/2015 - "As Wnt/β-catenin/glycogen synthase kinase 3β (GSK3β) signaling has been implicated in myocardial injury and diabetic cardiomyopathy (DCM) is a major part of diabetic cardiovascular complications, we therefore investigated the alterations of Wnt/β-catenin/GSK3β signaling during the development of DCM. "
01/01/2011 - "The present study was to investigate the role of kinin B2 receptor-Akt-glycogen synthase kinase (GSK)-3β signalling pathway in mediating the protective effects of tanshinone IIA (TSN) on diabetic cardiomyopathy. "
04/03/2006 - "Glycogen synthase kinase 3beta together with 14-3-3 protein regulates diabetic cardiomyopathy: effect of losartan and tempol."
|3.||Proto-Oncogene Proteins c-akt (Protein Kinase B)
|4.||4- benzyl- 2- methyl- 1,2,4- thiadiazolidine- 3,5- dione
|8.||Cyclooxygenase 2 (Cyclooxygenase-2)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|3.||Transplantation (Transplant Recipients)